PFI-RP: Innovation of Materials Based on Sustainable Resources to Enhance Performance of Challenging Drugs and Drug Candidates.

PFI-RP:基于可持续资源的材料创新,以提高挑战性药物和候选药物的性能。

基本信息

项目摘要

The broader impact/commercial potential of this PFI project is to enhance performance of the drugs that patients currently find on the pharmacist?s shelf, and to increase the number of effective new drugs that reach patients to treat critical medical issues. Currently up to 90% of drug candidates don?t fully dissolve in water, contributing to failure of otherwise effective candidates; all humans are roughly 70% water. We will design new materials, made from renewable resources and thus benign and environmentally sound, that solve key problems in drug delivery to patients. These currently unsolved problems include the inability to create patient-friendly formulations (pills) from drugs that require high doses (creating hard to swallow "horse pills"). Another important unsolved problem is failures of many drug candidates that tend to quickly form crystals from a water solution. When these drugs fail, cost of drug development goes up, which is ultimately passed along to patients. Drugs that would otherwise effectively treat diseases and are sorely needed by patients, never reach them. Our work will bring more drugs to patients, faster and more cheaply, and will reduce cost, side effects, dose, and variation in performance from patient to patient for drugs currently on the pharmacy shelf.The proposed project targets the design, preparation, and evaluation of two new families of materials prepared from natural cellulose, which is incredibly abundant, renewable, benign, and harvested in large quantities already from trees. These materials will be carefully designed so as to be easily made by current manufacturers of cellulose derivatives, and to work exceptionally well at enhancing the performance of drugs. They will be designed to help create solutions of current drugs, or drug candidates that are under development, that have far more dissolved drug per volume than is possible using current technologies. The ability to create these more concentrated solutions of drug or drug candidates in the human body will permit patients to get enough drug/drug candidate into their bloodstream to have the desired therapeutic effect, but at much lower drug dose. We will design, make, and characterize these materials, show that they work to create more concentrated solutions of key drugs, and figure out what features enhance their performance, so we can design even better materials. With our industrial partners, we will advance the best candidate materials towards commercialization so that they can benefit patients.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
该PFI项目更广泛的影响/商业潜力是提高患者目前在药剂师那里找到的药物的性能?的货架上,并增加有效的新药的数量,达到病人治疗关键的医疗问题。目前高达90%的候选药物不?由于水不能完全溶解在水中,导致其他有效的候选物失效;所有人大约70%是水。我们将设计新材料,由可再生资源制成,因此是良性和环保的,解决了向患者输送药物的关键问题。这些目前尚未解决的问题包括无法从需要高剂量的药物中创造出对患者友好的制剂(药丸)(创造出难以吞咽的“马药丸”)。另一个重要的未解决的问题是许多候选药物的失败,这些候选药物倾向于从水溶液中快速形成晶体。当这些药物失败时,药物开发的成本就会上升,最终沿着转嫁给患者。本来可以有效治疗疾病的药物和病人迫切需要的药物,从来没有到达他们手中。我们的工作将为患者带来更多的药物,更快,更便宜,并将降低成本,副作用,剂量,并从患者的性能差异,目前在药店货架上的药物。拟议中的项目的目标是设计,制备和评估两个新的家庭材料制备的天然纤维素,这是令人难以置信的丰富,可再生,良性,并已大量收获的树木。这些材料将被精心设计,以便易于由目前的纤维素衍生物制造商制造,并在提高药物性能方面发挥出色的作用。它们将被设计用于帮助创建当前药物或正在开发中的候选药物的解决方案,这些药物的单位体积溶解的药物远远超过使用当前技术的可能性。在人体中产生这些更浓缩的药物或药物候选物溶液的能力将允许患者将足够的药物/药物候选物进入他们的血流中以具有期望的治疗效果,但是以低得多的药物剂量。我们将设计、制造和表征这些材料,展示它们能为关键药物创造更浓缩的溶液,并找出哪些特性能提高它们的性能,这样我们就能设计出更好的材料。我们将与我们的工业合作伙伴一起,推动最佳候选材料的商业化,使其造福于患者。该奖项反映了NSF的法定使命,并通过使用基金会的知识价值和更广泛的影响审查标准进行评估,被认为值得支持。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Improved dissolution of an enteric polymer and its amorphous solid dispersions by polymer salt formation
  • DOI:
    10.1016/j.ijpharm.2022.121886
  • 发表时间:
    2022-06-12
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Qi, Qingqing;Taylor, Lynne S.
  • 通讯作者:
    Taylor, Lynne S.
Designing synergistic crystallization inhibitors: Bile salt derivatives of cellulose with enhanced hydrophilicity
设计协同结晶抑制剂:亲水性增强的纤维素胆盐衍生物
  • DOI:
    10.1016/j.carbpol.2022.119680
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Novo, Diana C.;Gao, Chengzhe;Qi, Qingqing;Mosquera-Giraldo, Laura I.;Spiering, Glenn A.;Moore, Robert B.;Taylor, Lynne S.;Edgar, Kevin J.
  • 通讯作者:
    Edgar, Kevin J.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kevin Edgar其他文献

3rd EPNOE international polysaccharide conference (EPNOE 2013)
  • DOI:
    10.1016/j.carbpol.2014.09.048
  • 发表时间:
    2015-02-13
  • 期刊:
  • 影响因子:
  • 作者:
    Kevin Edgar;Patrick Navard
  • 通讯作者:
    Patrick Navard
Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
  • DOI:
    10.1186/s12933-025-02741-5
  • 发表时间:
    2025-05-14
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Narainrit Karuna;Lauren Kerrigan;Kevin Edgar;Mark Ledwidge;Ken McDonald;David J. Grieve;Chris J. Watson
  • 通讯作者:
    Chris J. Watson
Dess-Martin oxidation of hydroxypropyl and hydroxyethyl cellulose, and exploration of their polysaccharide/polypeptide hydrogels
羟丙基纤维素和羟乙基纤维素的狄尔斯-阿尔德氧化反应及其多糖/多肽水凝胶的探索
  • DOI:
    10.1016/j.carbpol.2023.121732
  • 发表时间:
    2024-03-15
  • 期刊:
  • 影响因子:
    12.500
  • 作者:
    Jingyi Zhang;Shuo Wang;Ying Tang;Fujun Liu;Yongxian Zhao;Junyi Chen;Kevin Edgar
  • 通讯作者:
    Kevin Edgar

Kevin Edgar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kevin Edgar', 18)}}的其他基金

Collaborative Research: How do biopolymers dissolve? Identification of rate-limiting steps as a framework to design polymers with tailored dissolution.
合作研究:生物聚合物如何溶解?
  • 批准号:
    2204996
  • 财政年份:
    2022
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Standard Grant
Collaborative Research: Polysaccharide Derivatives for Enhanced Drug Delivery
合作研究:用于增强药物输送的多糖衍生物
  • 批准号:
    1308276
  • 财政年份:
    2013
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Standard Grant
Collaborative Research: Polysaccharide Derivatives for Enhanced Drug Delivery
合作研究:用于增强药物输送的多糖衍生物
  • 批准号:
    0804501
  • 财政年份:
    2008
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Continuing Grant

相似国自然基金

LncRNA RP11介导肿瘤细胞与肺驻留型巨 噬细胞互作抑制乳腺癌肺转移的机制研 究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
基于患者来源类器官模型探究基因编辑技术对PRPF6突变RP疾病的作用
  • 批准号:
    2025JJ90259
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
鼻咽解毒胶囊对鼻咽癌细胞生物学行为及IGFBP-rP1 mRNA表达的影响研究
  • 批准号:
    2025JJ80955
  • 批准年份:
    2025
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
m6A去甲基化酶FTO通过lncRNA RP5-991G20.1调控上皮性卵巢癌化疗耐药性的机制
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
USH2A基因突变位点c.8559-2A>G的功能学及其在 RP/USH II视网膜变性疾病的致病机制研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    15.0 万元
  • 项目类别:
    省市级项目
二甲双胍经TSPO介导的代谢重塑调控RP小胶质细胞稳态恢复的作用 机制研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
ISG15下调lncRNA RP11-5407.3介导细胞自噬促进子宫内膜癌进展的 作用及机制研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
RP相二维铅卤钙钛矿结构精细设计及其高稳定发光二极管基础研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    面上项目
肿瘤细胞经LncRNA-RP1/ATF4/CBS/CTH轴增加神经细胞半胱氨酸释放促进胰腺癌神经浸润的机制及治疗策略研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

PFI-RP: Crop Seed Shaped Pellets for Planting Multi-Species Conservation Habitats with Standard Planting Equipment
PFI-RP:作物种子形状颗粒,用于使用标准种植设备种植多物种保护栖息地
  • 批准号:
    2345771
  • 财政年份:
    2024
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Standard Grant
pre-insolvencyを含む「法的企業再建スキーム」の構築に向けて-英・RP手続を範として
以英国 RP 程序为模型,建立包括破产前在内的“合法企业重组计划”
  • 批准号:
    24K04656
  • 财政年份:
    2024
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
PFI-RP: Preventing Intimate Partner Violence Using Digital Technology: A Transdisciplinary Approach
PFI-RP:利用数字技术预防亲密伴侣暴力:跨学科方法
  • 批准号:
    2329797
  • 财政年份:
    2024
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Continuing Grant
PFI-RP: Resilient and Energy-Efficient Memory Chips for Enhanced Mobile AI and Personalized Machine Learning
PFI-RP:用于增强移动人工智能和个性化机器学习的弹性和节能内存芯片
  • 批准号:
    2345655
  • 财政年份:
    2024
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Standard Grant
PFI-RP: Novel Sensors for Efficient and Scalable Production of Indoor Crops
PFI-RP:用于高效、可规模化生产室内作物的新型传感器
  • 批准号:
    2329885
  • 财政年份:
    2023
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Continuing Grant
PFI-RP: The rapid and specific detection of infectious pathogens using ultrathin porous membranes as sensors
PFI-RP:使用超薄多孔膜作为传感器快速、特异性地检测传染性病原体
  • 批准号:
    2234394
  • 财政年份:
    2023
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Standard Grant
PFI-RP: Novel coated geotextile to enhance water drainage from soil
PFI-RP:新型涂层土工布,可增强土壤排水能力
  • 批准号:
    2234410
  • 财政年份:
    2023
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Standard Grant
PFI-RP: Precision diagnostics for personalized cancer care: development of new drugs and selection of treatment
PFI-RP:个性化癌症护理的精准诊断:新药开发和治疗选择
  • 批准号:
    2234456
  • 财政年份:
    2023
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Standard Grant
PFI-RP: Architectural design and intelligent control tools for decarbonizing space cooling and heating in buildings
PFI-RP:用于建筑物空间制冷和供暖脱碳的建筑设计和智能控制工具
  • 批准号:
    2234630
  • 财政年份:
    2023
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Standard Grant
PFI-RP: Development of a Temperature-Sensitive, High-Adhesion Medical Tape for Reducing Pain, Skin Injury, and Dislodgement of Critical Devices for Children in Hospitals
PFI-RP:开发一种温度敏感、高粘性医用胶带,用于减轻医院儿童的疼痛、皮肤损伤和关键设备的移位
  • 批准号:
    2234356
  • 财政年份:
    2023
  • 资助金额:
    $ 74.94万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了